5
Spain has become the first European country to publicly fund injectable pre-exposure prophylaxis (PrEP) for the prevention of HIV infection, a treatment option for individuals who are HIV-negative and at high risk of sexual transmission. This move expands access to preventative care and offers a new tool in the fight against HIV.
The Spanish Ministry of Health announced on Thursday, February 26, 2026, that the Interministerial Commission on Drug Prices (CIPM) approved public funding for the injectable PrEP, marketed as Apretude (cabotegravir extended-release). This decision positions Spain at the forefront of combined HIV prevention in Europe.
According to the Ministry’s statement, the injectable PrEP is administered every two months and eliminates the need for a daily pill, as is required with oral PrEP, potentially improving adherence among certain populations.
The treatment is indicated for individuals at high risk of infection, particularly those for whom oral PrEP is not a viable option.
International clinical trials have demonstrated that long-acting cabotegravir offers high efficacy in preventing HIV infection compared to daily oral regimens, especially in situations where consistent adherence can be challenging.
The European Medicines Agency (EMA) previously granted marketing authorization for the drug, making it available in member states.
This decision by the pricing and financing body ensures the medication will be incorporated into the National Health System as a covered benefit, with equitable and universal access.
The move aligns with recommendations from the World Health Organization (WHO) and UNAIDS, which advocate for expanded access to effective prevention strategies to advance toward the elimination of HIV as a public health problem.
